Log in

RACC Research Alliance Corp III NASDAQ · United States

Research Alliance Corp III (RACC) news

Research Alliance Corp III is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RACC, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Research Alliance Corp III news

We have not published a story on Research Alliance Corp III yet. When there is news, it will appear here.

Questions about Research Alliance Corp III

What is the ticker symbol of Research Alliance Corp III?

Research Alliance Corp III trades under the ticker RACC on NASDAQ.

Where is Research Alliance Corp III listed?

Research Alliance Corp III is listed on NASDAQ.

Which country or territory is Research Alliance Corp III listed under?

Our directory records Research Alliance Corp III under United States.

Does aibio.space cover Research Alliance Corp III?

aibio.space lists Research Alliance Corp III among 2,820 public biotech companies and publishes its news here as stories appear.

Investor discussion: Research Alliance Corp III

Members talk about Research Alliance Corp III (RACC). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Research Alliance Corp III, newest first. Each line links the filing it comes from.

  1. Mergers

    Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). Source

  2. Financings

    Reported a financing. SEC Form 424B4. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:RACC on TradingView.

Listing details

Research Alliance Corp III is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RACC, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Research Alliance Corp III
Ticker
RACC
Listing
NASDAQ
Country or territory
United States

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.